Blurbs

Nektar Therapeutics (NKTR) Gets a Hold from Stifel Nicolaus

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Nektar Therapeutics (NKTRResearch Report) yesterday and set a price target of $4.70. The company’s shares closed yesterday at $4.95.

Burnett covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, CTI BioPharma, and Atara Biotherapeutics. According to TipRanks, Burnett has an average return of -8.4% and a 33.33% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Nektar Therapeutics with a $4.75 average price target, representing a -4.04% downside. In a report released on August 5, SVB Securities also maintained a Hold rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $19.37 and a one-year low of $3.02. Currently, Nektar Therapeutics has an average volume of 3.29M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Read More on NKTR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More